Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4929-4934

  Park, Mi Sun ^a   Dong, Seung Myung ^a   Kim, Boh Ram ^a   Seo, Seung Hee ^a   Kang, Sokbom ^a   Lee, Eun Ju ^b   Lee, Seung Hoon ^c   Rho, Seung Bae ^a  

^a National Cancer Center   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Yongin University   (South Korea)

Author keywords

Anti angiogenic activity; Anti tumor effect; MTOR signaling; Thioridazine; Xenograft model

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; THIORIDAZINE; VASCULOTROPIN RECEPTOR 2; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; NEUROLEPTIC AGENT; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL FUNCTION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; IMMUNOBLOTTING; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; OVARIAN NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; THIORIDAZINE; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904962883     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2063     Document Type: Article

References (24)

1. Cowap J, Hardy J. Thioridazine in the management of cancer-related sweating. J. Pain Symptom Manage. 1998; 15: 266.
2. Zhukovsky DS. Fever and sweats in the patient with advanced cancer. Hematol. Oncol. Clin. North. Am. 2002; 16: 579-588.
3. Ly KL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: a systematic review. Part 2 Treatment. Palliat. Med. 2002; 16: 279-284.
4. Kamiwatari M, Nagata Y, Kikuchi H, Yoshimura A, Sumizawa T, Shudo N, Sakoda R, Seto K, Akiyama S. Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res. 1989; 49: 3190-3195.
5. Pantazaki AA, Lialiaris TS. A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids. Mutagenesis 1999; 14: 243-248.
6. Rho SB, Kim BR, Kang S. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol. Oncol. 2011; 120: 121-127.
7. Byun HY, Lee JH, Kim BR, Kang S, Dong SM, Park MS, Lee SH, Park SH, Rho SB. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc. Res. 2012; 84: 227-234.
8. Folkman J, Shing Y. Angiogenesis. J. Biol. Chem. 1992; 267: 10931-10934.
9. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
10. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002; 2: 795-803.
11. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996; 56: 2013-2016.
12. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J. Cell. Physiol. 2006; 209: 56-66.
13. Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, Vlahos CJ, Ye K, Perry BN, Matter W, Fischl A, Cook J, Silver PA, Bain J, Cohen P, Whitmire D, Furness S, Govindarajan B, Bowen JP. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood 2007; 109: 560-565.
14. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 2008; 1784: 150-158.
15. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell. Signal. 1998; 10: 233-239.
16. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 2000; 97: 1749-1753.
17. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002; 16: 1472-1487.
18. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
19. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004; 23: 2934-2949.
20. Breier G. Endothelial receptor tyrosine kinases involved in blood vessel development and tumor angiogenesis. Adv. Exp. Med. Biol. 2000; 476: 57-66.
21. Ferrara N. Rloe of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2002; 280: C1358-C1366.
22. Meyer RD, Rahimi N. Comparative structure-function analysis of VEGF-1 and VEGF-2. Ann. N. Y. Acad. Sci. 2003; 995: 200-207.
23. Meyer RD, Singh A, Majnoun F, Latz C, Lashkari K, Rahimi N. Substitution of C-terminal of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferation. Oncogene 2004; 23: 5523-5531.
24. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell. Signal. 1998; 10: 233-239.